NASDAQ$HRMY
Harmony Biosciences Holdings Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Reported financial results for the third quarter of 2021 and provided business updates.
Harmony Biosciences reported net product revenues of $80.7 million for the quarter ended September 30, 2021, a 77% increase compared to the same period in 2020. GAAP net loss available to shareholders was $9.6 million, or a loss of $0.17 per diluted share, while non-GAAP adjusted net income was $30.4 million, or $0.51 per diluted share.
- WAKIX net revenue was $80.7 million for Q3 2021, a 77% increase compared to Q3 2020.
- The average number of patients on WAKIX increased to approximately 3,500.
- WAKIX was included in the American Academy of Sleep Medicine's updated clinical practice guideline.
- A Phase 2 proof of concept clinical trial is evaluating pitolisant for EDS and other symptoms in patients with PWS, with top-line data expected in the first half of 2022.
Headline financials
Revenue & EPS history
Harmony Biosciences · Revenue · Quarterly
$80.7M
Revenue by segment
Harmony Biosciences · $80.7M total across 1 segment · Q3 2021
- WAKIX Net Product Revenue$80.7M+77.0%100.0%
Forward guidance
Harmony Biosciences did not provide specific forward guidance in this earnings report.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+1.3%
Avg return
Earnings day
+3.0%
Avg return
5 days after
+6.0%
Avg return
30 days after
54%
14 / 26 earnings
Positive
+24.4%
Q3 2023
Best reaction
-15.1%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.1% | -8.0% | -1.8% | |
| Q4 2025 | +2.6% | +6.2% | +2.1% | |
| Q3 2025 | -1.6% | -5.1% | +18.1% | |
| Q1 2025 | +7.0% | +13.7% | +16.9% | |
| Q4 2024 | +8.2% | -1.0% | -2.4% | |
| Q3 2024 | -5.5% | -7.5% | +0.0% | |
| Q2 2024 | +8.5% | +9.4% | +15.0% | |
| Q1 2024 | +3.5% | +7.9% | -1.3% | |
| Q4 2023 | -1.5% | +1.5% | +0.9% | |
| Q3 2023 | +24.4% | +31.5% | +47.4% | |
| Q2 2023 | -7.9% | -5.0% | +2.5% | |
| Q1 2023 | +9.9% | +9.5% | +5.0% | |
| Q4 2022 | -6.1% | -8.0% | -15.2% | |
| Q3 2022 | +12.5% | +13.2% | +15.4% | |
| Q2 2022 | +6.3% | +6.6% | -7.8% | |
| Q1 2022 | -15.1% | -21.9% | -5.0% | |
| Q4 2021 | +5.6% | +6.1% | +31.5% | |
| Q3 2021 | +0.1% | -0.1% | -9.3% | |
| Q2 2021 | +13.9% | +20.1% | +41.4% | |
| Q1 2021 | +1.2% | +4.0% | +21.8% | |
| Q1 2020 | +1.2% | +4.0% | +21.8% | |
| Q2 2020 | -4.1% | +11.4% | -2.1% | |
| Q4 2020 | -4.1% | +11.4% | -2.1% | |
| Q3 2020 | -6.8% | -7.4% | -12.0% | |
| Q4 2019 | -6.8% | -7.4% | -12.0% | |
| Q3 2019 | -6.8% | -7.4% | -12.0% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro